THE European Medicines Agency (EMA) is advising health professionals not to exceed the recommended dose of Xeljanz (tofacitinib) when treating rheumatoid arthritis.
The advice follows early results from an ongoing study which showed an increased risk of blood clots in the lungs and death when the normal dose of 5mg twice daily was doubled.
See ema.europa.eu for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Mar 19
